Quality of life in patients with multiple myeloma treated with percutaneous vertebroplasty

Abstract

OBJECTIVE: To determine the quality of life in patients with multiple myeloma treated with vertebroplasty. Multiple myeloma has a prevalence of 1% in all neoplastic diseases and 10% of hematological malignancies. Bone pain is the initial symptom in most cases. METHODS: A series of cases study was conducted. Patients were assessed by the Karnofsky scale to measure its functionality, the WHO analgesic scale to assess the type of analgesic and visual analog scale (VAS) and the Oswestry questionnaire for pain. RESULTS: Of 24 patients, 10 were cases (vertebroplasty) (41.7%) and 14 were controls (conservative) (58.3%), 13 (54.2%) were female and 11 (45.8%) male, with an average age of 60 years (SD = 12) and 63 kg of average weight (SD = 12), mean height of 1.59 cm (SD = 9) and mean body mass index of 24.8 (SD = 3.7). Survival was obtained from the time of diagnosis to death, and 2 (8.3%) patients died within the first 2 years and 1 (4.2%) after 3 years. CONCLUSIONS: Patients with MM who have vertebral fractures are excellent candidates to undergo vertebroplasty, because this represents a greater benefit in their quality of life, which has a direct impact on their level of functionality, giving them greater self-sufficiency and reducing their pain because of the benefits of the thermogenic effect of vertebroplasty.

Evaluación económica de denosumab en la prevención de eventos relacionados con el esqueleto en pacientes con mieloma múltiple en México

“…The probabilities of using the regimens considered in the analysis (thalidomide, bortezomib, thalidomide-bortezomib combination, chemotherapy with melphalan) for the first three lines of anti-myeloma treatment were estimated based on data published by de Moraes Hungria et al 30 . The calculation of costs contemplates the dosage recommended for each agent on the respective descriptive documents of the National Compendium of Health Supplies 31 , with the figures published by Bohsain being used as average values for height and body weight (160 cm and 63.7 kg, respectively) 32 , as well as acquisition costs estimated based on IMSS 2020 PAAASOP 24 . Thus, the cost for each 28 days of anti-myeloma treatment applied in the model was: $4,673.15 for first line, $5,948.95 for second line, and $5,532.63 for third line.…”

Intervenções Médicas No Parto Vaginal: Uma Revisão Integrativa

“…A glândula é dividida em duas porções: anterior, produtora de hormônios (GH, ACTH, TSH, prolactina, FSH e LH), e posterior, responsável pela secreção hormonal (ADH e ocitocina) 6 . Os adenomas pituitários são tumores benignos classificadas em funcionantes (75%) e não-funcionantes (25%), os primeiros mimetizam a função glandular e os segundos podem ser anatomicamente prejudiciais 8 3 . Hoje, apesar da abordagem endoscópica endonasal transesfenoidal apresentar melhores resultados e ser amplamente utilizada, ainda é considerada anticonvencional.…”

A Eficácia Da Câmara Hiperbarica No Tratamento De Lesões De Pele: Uma Revisão De Literatura

“…A glândula é dividida em duas porções: anterior, produtora de hormônios (GH, ACTH, TSH, prolactina, FSH e LH), e posterior, responsável pela secreção hormonal (ADH e ocitocina) 6 . Os adenomas pituitários são tumores benignos classificadas em funcionantes (75%) e não-funcionantes (25%), os primeiros mimetizam a função glandular e os segundos podem ser anatomicamente prejudiciais 8 . A exérese desses adenomas corresponde a 20% de todas as cirurgias intracranianas realizadas em tumorações cerebrais primárias 4 3 .…”

“…Diagnosis. Treatment.INTRODUÇÃOO Mieloma Múltiplo (MM) é uma neoplasia maligna hematopoiética, caracterizada por proliferação clonal de plasmócitos na medula óssea e destruição óssea extensa, gerando anemia, dores ósseas e fraturas (1) (2)(8).…”